ISLAMABAD — The Drug Regulatory Authority of Pakistan (DRAP) has issued an urgent nationwide safety alert regarding a counterfeit pediatric vaccine circulating in the market, posing significant health hazards to infants and young children. The regulatory body stepped in after receiving formal notifications from Hoechst Pakistan Limited, the local distributor for Sanofi, highlighting the unauthorized distribution of a falsified formulation intended to protect children against multiple infectious diseases.
According to the official advisory, the fraudulent medication has been identified as the Hexaxim vaccine carrying batch number X3H421VA. Crucially, the spurious product is being marketed in vial containers, whereas the legitimate vaccine is only authorized and registered within Pakistan in pre-filled syringe presentations. The six-in-one immunization protects vulnerable minors against diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis, and Haemophilus influenzae type b infections.
Health authorities have cautioned that administering this unverified batch could lead to severe medical complications, including adverse physical reactions and a failure to develop immunity against these dangerous pathogens. In response to the threat, DRAP has mobilized its specialized Regulatory Field Force alongside provincial drug control administrations to rigorously inspect the supply chain, track down the counterfeit items, and seize all identified units immediately.
Medical professionals, clinics, and parents have been strongly advised to exercise extreme caution and source medical products exclusively from licensed, authorized pharmacies. Citizens who suspect they have encountered the falsified batch or experienced adverse health effects are urged to consult a qualified physician immediately and report the occurrence directly to the National Pharmacovigilance Centre or DRAP officials.
